02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Oct 18, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Thyroid disease NK2 homeobox 1 (NKX2-1; TTF1); paired box gene 8 (PAX8) Studies in cell culture and in mice suggest embryonic stem cell (ESC)-derived...
07:00 , Mar 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) NK2 homeobox 1 (NKX2-1; TTF1); NKX2-8 In vitro studies suggest that gene expression profiles of...
08:00 , Feb 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Papillary thyroid carcinoma NK2 homeobox 1 (NKX2-1; TITF1) A screen of papillary thyroid carcinoma patients identified a germline mutation that could...